APA (7th ed.) Citation

Tschismarov, R., Van Damme, P., Germain, C., De Coster, I., Mateo, M., Reynard, S., . . . Baize, S. (2023). Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: A randomised, placebo-controlled, first-in-human trial. Lancet, 401(10384), 1267. https://doi.org/10.1016/S0140-6736(23)00048-X

Chicago Style (17th ed.) Citation

Tschismarov, Roland, et al. "Immunogenicity, Safety, and Tolerability of a Recombinant Measles-vectored Lassa Fever Vaccine: A Randomised, Placebo-controlled, First-in-human Trial." Lancet 401, no. 10384 (2023): 1267. https://doi.org/10.1016/S0140-6736(23)00048-X.

MLA (9th ed.) Citation

Tschismarov, Roland, et al. "Immunogenicity, Safety, and Tolerability of a Recombinant Measles-vectored Lassa Fever Vaccine: A Randomised, Placebo-controlled, First-in-human Trial." Lancet, vol. 401, no. 10384, 2023, p. 1267, https://doi.org/10.1016/S0140-6736(23)00048-X.